ERBB2 and breast carcinoma: Trastuzumab-TDB, similar to trastuzumab, has two arms, one binding to HER2 on breast cancer cells and the other binding to CD3 on T cells, thereby triggering an anti-tumor effect by inducing a strong intratumor immune response.